. 2011 Mar 15;203(6):780–790. doi: 10.1093/infdis/jiq118

Table 5.

No Significantly Increased Risk of AIDS events in HIV-Infected subjects conferred by markers of enterocyte damage, microbial translocation, or the immune response to microbial translocation at baseline.

		25^th – 49^th Percentile		50^th – 74^th Percentile		≥74^th Percentile
Biomarker	<25^th Percentile (Ref)	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
sCD14 level, ×10⁶ pg/mL)
N (case patients/control subjects)	17/43	20/41		23/39		21/39
Univariate OR	1.0	1.2 (0.6–2.5)	.65	1.5 (0.7–3.3)	0.28	1.4 (0.6–3.2)	.39
LPS level, pg/mL
N (case patients/control subjects)	22/38	13/48		24/38		22/38
Univariate OR	1.0	0.5 (0.2–1.1)	.08	1.1 (0.5–2.4)	0.83	1.0 (0.5–2.2)	>.99
I-FABP level, pg/mL
N (case patients/control subjects)	24/65	13/18		25/35		18/42
Univariate OR	1.0	2.0 (0.8–4.7)	.13	1.8 (0.9–3.7)	0.09	1.2 (0.6–2.5)	.68
16S rDNA level, copies/μL
N (case patients/control subjects)	18/41	18/43		18/42		26/35
Univariate OR	1.0	0.9 (0.4–2.1)	.88	0.9 (0.4–2.2)	0.90	1.7 (0.7–3.8)	.22
EndoCAb level, MMU/mL
N (case patients/control subjects)	21/39	24/37		18/43		18/43
Univariate OR	1.0	1.2 (0.6–2.5)	.60	0.8 (0.3–1.6)	0.47	0.8 (0.4–1.6)	.50

NOTE. Percentile cutoff points are LPS: <22.8, 22.8–32.1, 32.2–47.0, >47.0; soluble CD14: <2.06, 2.06–2.32, 2.33–2.68, >2.68; I-FABP: <2.70, 2.70–149.57, 149.57–468.00, >468.00; 16S ribosomal DNA: <3.8, 3.8–8.5, 8.6–15.0, >15.0; EndoCAb: <76.0, 76.0–128.0, 128.1–186.0, >186.0. CI, confidence interval; CVD, cardiovascular disease; EndoCAb, endotoxin core antibody; HIV, human immunodeficiency virus; I-FABP, intestinal fatty acid binding protein; LPS, lipopolysaccharide; OR, odds ratio; rDNA, ribosomal DNA; Ref, reference; sCD14, soluble CD14.